07:40 AM EDT, 03/26/2026 (MT Newswires) -- Tonix Pharmaceuticals ( TNXP ) said Thursday the first participant has been dosed in a phase 1 study of TNX-1900 to assess its potential for treating migraine and craniofacial pain.

The study will help evaluate the effect of the TNX-1900 intranasal potentiated oxytocin on trigeminal nerve-mediated vasodilation of the forehead using capsaicin, as well as electrical stimulation, in healthy female human volunteers.